Shares of BioNTech SE (BNTX) are surging over 48% in pre-market today, after the company and Pfizer Inc. (PFE) announced that the German regulatory authority, the Paul-Ehrlich-Institut, has approved the Phase 1/2 clinical trial for BioNTech's BNT162 vaccine program to prevent COVID-19 infection.
from RTT - Before the Bell https://ift.tt/2XTXu3R
via IFTTT
No comments:
Post a Comment